Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S 5 FORCES
4.2 PESTEL ANALYSIS
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 PATENT LANDSCAPE
5.1.2 USPTO NUMBER
5.1.3 PATENT EXPIRY
5.1.4 EPIO NUMBER
5.1.5 PATENT STRENGTH AND QUALITY
5.1.6 PATENT CLAIMS
5.1.7 PATENT CITATIONS
5.1.8 PATENT LITIGATION AND LICENSING
5.1.9 FILE OF PATENT
5.1.10 PATENT RECEIVED CONTRIES
5.1.11 TECHNOLOGY BACKGROUND
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.4 PATIENT FLOW DIAGRAM
5.5 KEY PRICING STRATEGIES
5.6 KEY PATIENT ENROLLMENT STRATEGIES
5.7 INTERVIEWS WITH SPECIALIST
5.8 OTHER KOL SNAPSHOTS
6 EPIDEMOLOGY
6.1 INCIDENCE RATE
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATIENT TREATMENT SUCCESS RATES
7 MERGERS AND ACQUISITION
7.1 LICENSING
7.2 COMMERCIALIZATION AGREEMENTS
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES' EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR XX
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
10 MARKETED DRUG ANALYSIS
10.1 DRUG
10.1.1 BRAND NAME
10.1.2 GENERICS NAME
10.2 THERAPEUTIC INDIACTION
10.3 PHARACOLOGICAL CLASS OD THE DRUG
10.4 DRUG PRIMARY INDICATION
10.5 MARKET STATUS
10.6 MEDICATION TYPE
10.7 DRUG DOSAGES FORM
10.8 DOSAGES AVAILABILITY
10.9 PACKAGING TYPE
10.1 DRUG ROUTE OF ADMINISTRATION
10.11 DOSING FREQUENCY
10.12 DRUG INSIGHT
10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
10.13.1 FORECAST MARKET OUTLOOK
10.13.2 CROSS COMPETITION
10.13.3 THERAPEUTIC PORTFOLIO
10.14 CURRENT DEVELOPMENT SCENARIO
11 MARKET OVERVIEW
11.1 DRIVERS
11.2 RESTRAINS
11.3 OPPURTUNITY
11.4 CHALLENGES
12 MARKET ACCESS
12.1 10-YEAR MARKET FORECAST
12.2 CLINICAL TRIAL RECENT UPDATES
12.3 ANNUAL NEW FDA APPROVED DRUGS
12.4 DRUGS MANUFACTURER AND DEALS
12.5 MAJOR DRUG UPTAKE
12.6 CURRENT TREATMENT PRACTICES
12.7 IMPACT OF UPCOMING THERAPY
13 R & D ANALYSIS
13.1 COMPARATIVE ANALYSIS
13.2 DRUG DEVELOPMENTAL LANDSCAPE
13.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
13.4 THERAPEUTIC ASSESSMENT
13.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
14 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, BY DIAGNOSIS AND TREATMENT
(NOTE: MARKET VALUE, VOLUME AND ASP ANALYSIS WOULD BE PROVIDED FOR ALL SEGMENTS AND SUB-SEGMENTS OF PRODUCT)
14.1 OVERVIEW
14.2 DIAGNOSIS
14.2.1 BLOOD TESTS
14.2.1.1. CREATININE
14.2.1.2. OTHER BIOMARKERS
14.2.2 URINE TESTS
14.2.2.1. DIPSTICK TEST FOR ALBUMIN
14.2.2.2. URINE ALBUMIN-TO-CREATININE RATIO (UACR)
14.2.3 IMAGING TESTS
14.2.3.1. X-RAYS
14.2.3.2. PYELOGRAPHY
14.2.3.3. ULTRASONOGRAPHY
14.2.3.4. COMPUTED TOMOGRAPHY
14.2.3.5. OTHERS
14.2.4 BIOPSY
14.2.4.1. OPEN KIDNEY BIOPSY
14.2.4.2. PERCUTANEOUS KIDNEY BIOPSY
14.2.4.3. LAPAROSCOPIC KIDNEY BIOPSY
14.2.4.4. TRANSJUGULAR KIDNEY BIOPSY
14.3 TREATMENT
14.3.1 MEDICATION
14.3.1.1. MEDICATION, BY TYPE
14.3.1.1.1. SGLT2 INHIBITORS
14.3.1.1.1.1 DAPAGLIFLOZIN
14.3.1.1.1.2 OTHERS
14.3.1.1.2. ACE INHIBITORS
14.3.1.1.2.1 BENAZEPRIL
14.3.1.1.2.2 CAPTOPRIL
14.3.1.1.2.3 ENALAPRIL
14.3.1.1.2.4 CAPTOPRIL
14.3.1.1.2.5 LISINOPRIL
14.3.1.1.2.6 CAPTOPRIL
14.3.1.1.2.7 CAPTOPRIL
14.3.1.1.2.8 OTHERS
14.3.1.1.3. BETA BLOCKERS
14.3.1.1.3.1 ACEBUTOLOL
14.3.1.1.3.2 ATENOLOL
14.3.1.1.3.3 BISOPROLOL
14.3.1.1.3.4 NADOLOL
14.3.1.1.4. NADOLOL
14.3.1.1.4.1 AMILORIDE
14.3.1.1.4.2 BUMETANIDE
14.3.1.1.4.3 FUROSEMIDE
14.3.1.1.4.4 METOLAZONE
14.3.1.1.4.5 SPIRONOLACTONE
14.3.1.1.4.6 THIAZIDES
14.3.1.1.4.7 TORSEMIDE
14.3.1.1.4.8 TRIAMTERENE
14.3.1.1.5. ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)
14.3.1.1.5.1 EPOETIN ALFA
14.3.1.1.5.2 EPOETIN BETA
14.3.1.1.5.3 DARBEPOETIN ALFA
14.3.1.1.5.4 OTHERS
14.3.1.1.6. ANTIBIOTICS
14.3.1.1.6.1 CEFTRIAXONE
14.3.1.1.6.2 CLINDAMYCIN
14.3.1.1.6.3 DOXYCYCLINE
14.3.1.1.6.4 MOXIFLOXACIN
14.3.1.1.6.5 AZITHROMYCIN
14.3.1.1.6.6 CIPROFLOXACIN
14.3.1.1.6.7 LEVOFLOXACIN
14.3.1.1.6.8 OTHERS
14.3.1.1.7. DIURETICS
14.3.1.1.8. PHOSPHATE BINDERS
14.3.1.1.9. OTHERS
14.3.1.2. MEDICATION, BY ROUTE OF ADMINISTRATION
14.3.1.2.1. ORAL
14.3.1.2.1.1 TABLETS
14.3.1.2.1.2 CAPSULES
14.3.1.2.2. PARENTERAL
14.3.1.2.2.1 INTRAVENOUS
14.3.1.2.2.2 SUBCUTANEOUS
14.3.1.2.2.3 OTHER
14.3.1.2.3. OTHERS
14.3.1.3. MEDICATION, BY PRODUCT TYPE
14.3.1.3.1. BRANDED/ REFERENCE DRUG
14.3.1.3.1.1 KARENDIA
14.3.1.3.1.2 CAPOTEN
14.3.1.3.1.3 PRINIVIL
14.3.1.3.1.4 DAPRUDUSTAT
14.3.1.3.1.5 DIOVAN
14.3.1.3.1.6 SECTRAL
14.3.1.3.1.7 JARDIANCE
14.3.1.3.1.8 BYSTOLIC
14.3.1.3.1.9 COREG
14.3.1.3.1.10 CRESTOR
14.3.1.3.1.11 FARXIGA
14.3.1.3.1.12 OTHERS
14.3.1.3.2. GENERIC/ BIOSIMILAR DRUG
14.3.1.3.2.1 QUINAPRIL
14.3.1.3.2.2 CANDESARTAN
14.3.1.3.2.3 NEBIVOLOL
14.3.1.3.2.4 ROSUVASTATIN
14.3.1.3.2.5 OTHERS
14.3.1.4. MEDICATION, BY PRESCRIPTION TYPE
14.3.1.4.1. PRESCRIPTION DRUG
14.3.1.4.2. OTC DRUG
14.3.2 DIALYSIS
14.3.2.1. HEMODIALYSIS
14.3.2.1.1. CENTER-USE HEMODIALYSIS
14.3.2.1.2. HOME-USE HEMODIALYSIS
14.3.2.2. PERITONEAL DIALYSIS
14.3.2.2.1. CENTER-USE HEMODIALYSIS
14.3.2.2.2. HOME-USE HEMODIALYSIS
14.3.3 KIDNEY TRANSPLANTATION
14.3.3.1. DECEASED-DONOR KIDNEY TRANSPLANTS
14.3.3.2. LIVING-DONOR KIDNEY TRANSPLANTS
15 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, BY STAGE
15.1 OVERVIEW
15.2 STAGE 1
15.2.1 DIAGNOSIS
15.2.2 TREATMENT
15.3 STAGE 2
15.3.1 DIAGNOSIS
15.3.2 TREATMENT
15.4 STAGE 3
15.4.1 DIAGNOSIS
15.4.2 TREATMENT
15.5 STAGE 4
15.5.1 DIAGNOSIS
15.5.2 TREATMENT
15.6 STAGE 5
15.6.1 DIAGNOSIS
15.6.2 TREATMENT
16 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, BY AGE GROUP
16.1 OVERVIEW
16.2 PEDIATRIC
16.3 ADULT
16.4 GERIATRIC
17 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, BY GENDER
17.1 OVERVIEW
17.2 MALE
17.3 FEMALE
18 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, BY END USER
18.1 OVERVIEW
18.2 HOSPITALS
18.2.1 PRIVATE
18.2.1.1. TIER 1
18.2.1.2. TIER 2
18.2.1.3. TIER 3
18.2.2 PUBLIC
18.2.2.1. TIER 1
18.2.2.2. TIER 2
18.2.2.3. TIER 3CLINICS
18.3 DIAGNOSTIC CENTERS
18.4 DIALYSIS CENTERS
18.5 HOMECARE SETTINGS
18.6 OTHERS
19 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, BY DISTRIBUTION CHANNEL
19.1 OVERVIEW
19.2 DIRECT TENDER
19.2.1 HOSPITAL PHARMACY
19.2.2 ONLINE PHARMACY
19.2.3 RETAIL PHARMACY
19.3 OTHERS
20 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, SWOT AND DBMR ANALYSIS
21 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, COMPANY LANDSCAPE
21.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
21.2 COMPANY SHARE ANALYSIS: EUROPE
21.3 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
21.4 MERGERS & ACQUISITIONS
21.5 NEW PRODUCT DEVELOPMENT & APPROVALS
21.6 EXPANSIONS
21.7 REGULATORY CHANGES
21.8 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
22 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, BY GEOGRAPHY
22.1 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
22.2 NORTH AMERICA
22.2.1 U.S.
22.2.1.1. U.S. CHRONIC KIDNEY DISEASE (CKD) MARKET, BY DIAGNOSIS AND TREATMENT
22.2.1.2. U.S. CHRONIC KIDNEY DISEASE (CKD) MARKET, BY STAGE
22.2.1.3. U.S. CHRONIC KIDNEY DISEASE (CKD) MARKET, BY AGE GROUP
22.2.1.4. U.S. CHRONIC KIDNEY DISEASE (CKD) MARKET, BY GENDER
22.2.1.5. U.S. CHRONIC KIDNEY DISEASE (CKD) MARKET, BY END USER
22.2.1.6. U.S. CHRONIC KIDNEY DISEASE (CKD) MARKET, BY DISTRUBUTION CHANNEL
22.2.2 CANADA
22.2.3 MEXICO
22.3 EUROPE
22.3.1 GERMANY
22.3.2 FRANCE
22.3.3 U.K.
22.3.4 HUNGARY
22.3.5 LITHUANIA
22.3.6 AUSTRIA
22.3.7 IRELAND
22.3.8 NORWAY
22.3.9 POLAND
22.3.10 ITALY
22.3.11 SPAIN
22.3.12 RUSSIA
22.3.13 TURKEY
22.3.14 NETHERLANDS
22.3.15 SWITZERLAND
22.3.16 REST OF EUROPE
22.4 ASIA-PACIFIC
22.4.1 JAPAN
22.4.2 CHINA
22.4.3 SOUTH KOREA
22.4.4 INDIA
22.4.5 AUSTRALIA
22.4.6 SINGAPORE
22.4.7 THAILAND
22.4.8 MALAYSIA
22.4.9 INDONESIA
22.4.10 PHILIPPINES
22.4.11 VIETNAM
22.4.12 REST OF ASIA-PACIFIC
22.5 SOUTH AMERICA
22.5.1 BRAZIL
22.5.2 ARGENTINA
22.5.3 PERU
22.5.4 COLOMBIA
22.5.5 VENEZUELA
22.5.6 REST OF SOUTH AMERICA
22.6 MIDDLE EAST AND AFRICA
22.6.1 SOUTH AFRICA
22.6.2 SAUDI ARABIA
22.6.3 UAE
22.6.4 EGYPT
22.6.5 KUWAIT
22.6.6 ISRAEL
22.6.7 REST OF MIDDLE EAST AND AFRICA
22.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
23 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, COMPANY PROFILE
23.1 PFIZER INC.
23.1.1 COMPANY OVERVIEW
23.1.2 REVENUE ANALYSIS
23.1.3 GEOGRAPHIC PRESENCE
23.1.4 PRODUCT PORTFOLIO
23.1.5 RECENT DEVELOPMENTS
23.2 AMGEN INC.
23.2.1 COMPANY OVERVIEW
23.2.2 REVENUE ANALYSIS
23.2.3 GEOGRAPHIC PRESENCE
23.2.4 PRODUCT PORTFOLIO
23.2.5 RECENT DEVELOPMENTS
23.3 F. HOFFMANN-LA ROCHE LTD.
23.3.1 COMPANY OVERVIEW
23.3.2 REVENUE ANALYSIS
23.3.3 GEOGRAPHIC PRESENCE
23.3.4 PRODUCT PORTFOLIO
23.3.5 RECENT DEVELOPMENTS
23.4 ABBOTT.
23.4.1 COMPANY OVERVIEW
23.4.2 REVENUE ANALYSIS
23.4.3 GEOGRAPHIC PRESENCE
23.4.4 PRODUCT PORTFOLIO
23.4.5 RECENT DEVELOPMENTS
23.5 BRISTOL-MYERS SQUIBB COMPANY
23.5.1 COMPANY OVERVIEW
23.5.2 REVENUE ANALYSIS
23.5.3 GEOGRAPHIC PRESENCE
23.5.4 PRODUCT PORTFOLIO
23.5.5 RECENT DEVELOPMENTS
23.6 GSK PLC.
23.6.1 COMPANY OVERVIEW
23.6.2 REVENUE ANALYSIS
23.6.3 GEOGRAPHIC PRESENCE
23.6.4 PRODUCT PORTFOLIO
23.6.5 RECENT DEVELOPMENTS
23.7 FRESENIUS MEDICAL CARE
23.7.1 COMPANY OVERVIEW
23.7.2 REVENUE ANALYSIS
23.7.3 GEOGRAPHIC PRESENCE
23.7.4 PRODUCT PORTFOLIO
23.7.5 RECENT DEVELOPMENTS
23.8 KISSEI PHARMACEUTICAL CO., LTD.
23.8.1 COMPANY OVERVIEW
23.8.2 REVENUE ANALYSIS
23.8.3 GEOGRAPHIC PRESENCE
23.8.4 PRODUCT PORTFOLIO
23.8.5 RECENT DEVELOPMENTS
23.9 ASTRAZENECA
23.9.1 COMPANY OVERVIEW
23.9.2 REVENUE ANALYSIS
23.9.3 GEOGRAPHIC PRESENCE
23.9.4 PRODUCT PORTFOLIO
23.9.5 RECENT DEVELOPMENTS
23.1 MERCK & CO., INC.
23.10.1 COMPANY OVERVIEW
23.10.2 REVENUE ANALYSIS
23.10.3 GEOGRAPHIC PRESENCE
23.10.4 PRODUCT PORTFOLIO
23.10.5 RECENT DEVELOPMENTS
23.11 OTSUKA PHARMACEUTICAL CO., LTD.
23.11.1 COMPANY OVERVIEW
23.11.2 REVENUE ANALYSIS
23.11.3 GEOGRAPHIC PRESENCE
23.11.4 PRODUCT PORTFOLIO
23.11.5 RECENT DEVELOPMENTS
23.12 JOHNSON & JOHNSON
23.12.1 COMPANY OVERVIEW
23.12.2 REVENUE ANALYSIS
23.12.3 GEOGRAPHIC PRESENCE
23.12.4 PRODUCT PORTFOLIO
23.12.5 RECENT DEVELOPMENTS
23.13 FIBROGEN, INC.
23.13.1 COMPANY OVERVIEW
23.13.2 REVENUE ANALYSIS
23.13.3 GEOGRAPHIC PRESENCE
23.13.4 PRODUCT PORTFOLIO
23.13.5 RECENT DEVELOPMENTS
23.14 SIEMENS HEALTHCARE PRIVATE LIMITED
23.14.1 COMPANY OVERVIEW
23.14.2 REVENUE ANALYSIS
23.14.3 GEOGRAPHIC PRESENCE
23.14.4 PRODUCT PORTFOLIO
23.14.5 RECENT DEVELOPMENTS
23.15 NOVA BIOMEDICAL
23.15.1 COMPANY OVERVIEW
23.15.2 REVENUE ANALYSIS
23.15.3 GEOGRAPHIC PRESENCE
23.15.4 PRODUCT PORTFOLIO
23.15.5 RECENT DEVELOPMENTS
23.16 LUPIN
23.16.1 COMPANY OVERVIEW
23.16.2 REVENUE ANALYSIS
23.16.3 GEOGRAPHIC PRESENCE
23.16.4 PRODUCT PORTFOLIO
23.16.5 RECENT DEVELOPMENTS
23.17 ZYDUS GROUP
23.17.1 COMPANY OVERVIEW
23.17.2 REVENUE ANALYSIS
23.17.3 GEOGRAPHIC PRESENCE
23.17.4 PRODUCT PORTFOLIO
23.17.5 RECENT DEVELOPMENTS
23.18 BAYER AG
23.18.1 COMPANY OVERVIEW
23.18.2 REVENUE ANALYSIS
23.18.3 GEOGRAPHIC PRESENCE
23.18.4 PRODUCT PORTFOLIO
23.18.5 RECENT DEVELOPMENTS
23.19 AKEBIA THERAPEUTICS, INC.
23.19.1 COMPANY OVERVIEW
23.19.2 REVENUE ANALYSIS
23.19.3 GEOGRAPHIC PRESENCE
23.19.4 PRODUCT PORTFOLIO
23.19.5 RECENT DEVELOPMENTS
23.2 CSL VIFOR
23.20.1 COMPANY OVERVIEW
23.20.2 REVENUE ANALYSIS
23.20.3 GEOGRAPHIC PRESENCE
23.20.4 PRODUCT PORTFOLIO
23.20.5 RECENT DEVELOPMENTS
23.21 NOVARTIS
23.21.1 COMPANY OVERVIEW
23.21.2 REVENUE ANALYSIS
23.21.3 GEOGRAPHIC PRESENCE
23.21.4 PRODUCT PORTFOLIO
23.21.5 RECENT DEVELOPMENTS
23.22 SANOFI
23.22.1 COMPANY OVERVIEW
23.22.2 REVENUE ANALYSIS
23.22.3 GEOGRAPHIC PRESENCE
23.22.4 PRODUCT PORTFOLIO
23.22.5 RECENT DEVELOPMENTS
23.23 REATA PHARMACEUTICALS
23.23.1 COMPANY OVERVIEW
23.23.2 REVENUE ANALYSIS
23.23.3 GEOGRAPHIC PRESENCE
23.23.4 PRODUCT PORTFOLIO
23.23.5 RECENT DEVELOPMENTS
23.24 TRICIDA, INC.
23.24.1 COMPANY OVERVIEW
23.24.2 REVENUE ANALYSIS
23.24.3 GEOGRAPHIC PRESENCE
23.24.4 PRODUCT PORTFOLIO
23.24.5 RECENT DEVELOPMENTS
23.25 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.
23.25.1 COMPANY OVERVIEW
23.25.2 REVENUE ANALYSIS
23.25.3 GEOGRAPHIC PRESENCE
23.25.4 PRODUCT PORTFOLIO
23.25.5 RECENT DEVELOPMENTS
23.26 ARDELYX
23.26.1 COMPANY OVERVIEW
23.26.2 REVENUE ANALYSIS
23.26.3 GEOGRAPHIC PRESENCE
23.26.4 PRODUCT PORTFOLIO
23.26.5 RECENT DEVELOPMENTS
23.27 CARA THERAPEUTICS.
23.27.1 COMPANY OVERVIEW
23.27.2 REVENUE ANALYSIS
23.27.3 GEOGRAPHIC PRESENCE
23.27.4 PRODUCT PORTFOLIO
23.27.5 RECENT DEVELOPMENTS
23.28 CALLIDITAS THERAPEUTICS AB.
23.28.1 COMPANY OVERVIEW
23.28.2 REVENUE ANALYSIS
23.28.3 GEOGRAPHIC PRESENCE
23.28.4 PRODUCT PORTFOLIO
23.28.5 RECENT DEVELOPMENTS
23.29 TRAVERE THERAPEUTICS
23.29.1 COMPANY OVERVIEW
23.29.2 REVENUE ANALYSIS
23.29.3 GEOGRAPHIC PRESENCE
23.29.4 PRODUCT PORTFOLIO
23.29.5 RECENT DEVELOPMENTS
23.3 OMEROS CORPORATION
23.30.1 COMPANY OVERVIEW
23.30.2 REVENUE ANALYSIS
23.30.3 GEOGRAPHIC PRESENCE
23.30.4 PRODUCT PORTFOLIO
23.30.5 RECENT DEVELOPMENTS
24 RELATED REPORTS
25 CONCLUSION
26 QUESTIONNAIRE
27 ABOUT DATA BRIDGE MARKET RESEARCH
